SlideShare a Scribd company logo
HIV in Philadelphia
Kathleen A. Brady, MD
Medical Director/Medical Epidemiologist
AIDS Activities Coordinating Office
Philadelphia Department of Public Health
Office of HIV Planning Epi Update
February 9, 2017
THE HIV CARE CONTINUUM
HIV Care Continuum
Adapted from
Eldred et al AIDS Patient Care STDs 2007;21(Suppl1):S1-S2
Cheever LW Clin Infect Dis 2007;44:1500-2
Not in HIV Care Engaged in HIV Care
Unaware of
HIV infection
Aware of
HIV infection
(not in care)
Receiving some
medical care but
not HIV care
Entered HIV
care but lost to
follow-up
Cyclical or
intermittent user
of HIV care
Fully engaged
in HIV care
CDC HIV Continuum Measures
 Aligns with NHAS 2020 indicator definitions
 Represents the best available data for measuring progress
 Uses National HIV Surveillance System (NHSS) data which meet the NHAS
indicator data source criteria
– Timely and routine
– Can stratify by demographic characteristics
– Prioritized data sources that are available at the state level to allow
states ability to monitor progress toward Strategy goals in their
jurisdictions
 Uses different denominators for each measure
Calculation of Indicators
 Prevalence of diagnosed HIV – United States
– Numerator: Persons aged ≥13 years living with diagnosed HIV
infection year-end 2013
– Denominator: Persons aged ≥13 years living with diagnosed or
undiagnosed HIV infection year-end 2013 (derived using back-
calculation)
 The following indicators only use data from areas with complete
reporting of CD4 and viral load test results to CDC (32 states and the
District of Columbia):
– Linkage to care (within 1 month)
– Retention in care
– Viral suppression
Diagnosed Infection among Persons Aged ≥13 Years Living with Diagnosed or
Undiagnosed HIV Infection, by Sex, 2013—United States
Note. Data include persons with a diagnosis of HIV infection regardless of stage of disease at diagnosis. Estimates were derived by using back-
calculation on HIV data for persons aged ≥13 years at diagnosis in the 50 states and the District of Columbia.
Diagnosed Infection among Persons Aged ≥13 Years Living with Diagnosed or
Undiagnosed HIV Infection, by Age, 2013—United States
Note. Data include persons with a diagnosis of HIV infection regardless of stage of disease at diagnosis. Estimates were derived by using back-
calculation on HIV data for persons aged ≥13 years at diagnosis in the 50 states and the District of Columbia.
Unaware Estimates by Select Demographic
Groups, Philadelphia, 2014
Demographic Group % Unaware (95% CI)
Sex
Female 4.7% (0.0 %-9.8%)
Male 7.7% (3.8%-11.2%)
Race/Ethnicity
Black 8.5% (4.3%-12.4%)
Hispanic 4.4% (0%-11.4%)
White/Other 5.2% (0.1%-12.2%)
Mode of Transmission
Heterosexual 9.5% (9.0%-19.1%)
IDU (including MSM/IDU) 0.0% (0.0%-2.2%)
MSM 9.2% (4.0%-15.0%)
Total 7.0% (4.0% – 10.4%)
Source: PDPH, AIDS Activities Coordinating Office, 2016
EMA Concurrent HIV/AIDS
29.7% 29.1%
26.1% 24.9% 23.5%
0.0%
10.0%
20.0%
30.0%
40.0%
50.0%
2011 2012 2013 2014 2015
Philly PA Counties NJ Counties EMA
Concurrent HIV/AIDS, 2014 - 2015
Year
2014 2015
Non-concurrent Concurrent HIV/AIDS Non-concurrent Concurrent HIV/AIDS
N Col % N Col % N Col % N Col %
Total 444 78.0% 125 22.0% 433 80.5% 105 19.5%
Sex
Female 89 74.2% 31 25.8% 95 80.5% 23 19.5%
Male 35 79.1% 94 20.9% 338 80.5% 82 19.5%
Race/
Ethnicity
Black 294 76.2% 92 23.8% 312 80.0% 78 20.0%
Hispanic 63 88.7% 8 11.3% 66 86.8% 10 13.2%
White 70 80.5% 17 19.5% 46 82.1% 10 17.9%
Asian 10 76.9% * 23.1% * 45.5% 6 54.5%
Multi-race * 50.0% * 50.0% * 50.0% * 50.0%
Other/Unk * 75.0% * 25.0% * 100.0% 0 0.0%
Source: PDPH, AIDS Activities Coordinating Office, 2016
Concurrent HIV/AIDS, 2014 - 2015Year
2014 2015
Non-concurrent Concurrent HIV/AIDS Non-concurrent Concurrent HIV/AIDS
N Col % N Col % N Col % N Col %
Age at HIV Dx
0-12 * 100.0% 0 0.0% * 100.0% 0 0.0%
13-19 31 93.9% * 6.1% 33 97.1% * 2.9%
20-24 101 91.8% 9 8.2% 96 95.0% * 5.0%
25-29 77 88.5% 10 11.5% 81 88.0% 11 12.0%
30-39 89 74.2% 31 25.8% 101 78.3% 28 21.7%
40-49 62 63.9% 35 36.1% 57 64.8% 31 35.2%
50+ 83 68.6% 38 31.4% 63 68.5% 29 31.5%
Transmission
Risk
MSM 247 84.9% 44 15.1% 253 83.2% 51 16.8%
IDU 33 82.5% 7 17.5% 27 90.0% * 10.0%
Heterosexual 153 68.0% 72 32.0% 142 75.1% 47 24.9%
MSM/IDU 6 100.0% 0 0.0% * 50.0% * 50.0%
Pediatric * 100.0% 0 0.0% * 100.0% 0 0.0%
No Risk
Reported
* 66.7% * 33.3% 8 72.7% * 27.3%
Source: PDPH, AIDS Activities Coordinating Office, 2016
Calculation of Indicators
 Linkage to care
– Numerator: Persons aged ≥13 years who were diagnosed during 2014
and who had ≥1 viral load (VL) or CD4 test within 1 month of HIV
diagnosis
– Denominator: Persons aged ≥13 years who were diagnosed during 2014
(32 states and the District of Columbia)
Linkage to HIV Medical Care within 1 Month after HIV Diagnosis during 2014,
among Persons Aged ≥13 Years, by Sex—32 States and the District of Columbia
Note. Data include persons with a diagnosis of HIV infection regardless of stage of disease at diagnosis. Linkage to HIV medical care was defined as
having a CD4 or VL test ≤1 month after HIV diagnosis.
Linkage to HIV Medical Care within 1 Month after HIV Diagnosis during 2014,
among Persons Aged ≥13 Years, by Transmission Category—32 States and the
District of Columbia
Note. Data include persons with a diagnosis of HIV infection regardless of stage of disease at diagnosis. Linkage to HIV medical care was defined as
having a CD4 or VL test ≤1 month after HIV diagnosis. Heterosexual contact is with a person known to have, or be at high risk for, HIV infection.
MSM, male-to-male sexual contact; IDU, injection drug use
2011 2012 2013 2014 2015
Linkage 30 Days 75 75 72 77 81
Linkage 90 Days 81 81 78 82 91
0
20
40
60
80
100
Percentage(%) Care Continuum Measures
Source: Philadelphia Department of Public Health, AIDS Activities Coordinating Office
Philadelphia Linkage to Care Indicators, 2011-2015
Calculation of Indicators
 Retention in care
– Numerator: Persons aged ≥13 years with ≥2 tests (CD4 or VL) at least ≥3
months apart in 2013
– Denominator: Persons aged ≥13 years who were diagnosed by year-end
2012 and alive at year-end 2013 (32 states and the District of Columbia)
 Viral suppression
– Numerator: Persons aged ≥13 years with <200 copies/mL on their most
recent VL test in 2013
– Denominator: Persons aged ≥13 years who were diagnosed by year-end
2012 and alive at year-end 2013 (32 states and the District of Columbia)
Retention in HIV Medical Care and Viral Suppression among Persons Aged ≥13
Years Living with Diagnosed HIV Infection, by Sex, 2013—32 States and the
District of Columbia
Note. Data include persons with a diagnosis of HIV infection regardless of stage of disease at diagnosis. Retained in medical care was defined as ≥2
tests (CD4 or VL) ≥3 months apart in 2013. Viral suppression was defined as <200 copies/mL on the most recent VL test in 2013.
Retention in HIV Medical Care and Viral Suppression among Persons Aged ≥13
Years Living with Diagnosed HIV Infection, by Transmission Category, 2013—32
States and the District of Columbia
Note. Data include persons with a diagnosis of HIV infection regardless of stage of disease at diagnosis. Retained in medical care was defined as ≥2
tests (CD4 or VL) ≥3 months apart in 2013. Viral suppression was defined as <200 copies/mL on the most recent VL test in 2013. Heterosexual
contact is with a person known to have, or be at high risk for, HIV infection. MSM, male-to-male sexual contact; IDU, injection drug use
2011 2012 2013 2014 2015
Retention* 47 51 52 52 53
Suppression* 44 49 50 53 56
0
20
40
60
80
100
Percentage(%) Care Continuum Measures
*Significant increase between 2011 and 2015 (p<0.0001)
Philadelphia Diagnosis-Based HIV Care Continuum, 2011-2015
Source: Philadelphia Department of Public Health, AIDS Activities Coordinating Office
87%
75%
49% 48%
0%
20%
40%
60%
80%
100%
HIV-Diagnosed Linked to Care
(2015 New Cases)
In HIV Care
during 2015
Suppressed VL
(<200copies/mL)
US Prevalence-Based HIV Care Continuum, 2013
Source: Philadelphia Department of Public Health, AIDS Activities Coordinating Office
93% 91%
49% 52%
0%
20%
40%
60%
80%
100%
HIV-Diagnosed Linked to Care
(2015 New Cases)
In HIV Care
during 2015
Suppressed VL
(<200copies/mL)
19,280 488/538
10,173 10,758
Philadelphia Prevalence-Based HIV Care
Continuum, 2015
Source: Philadelphia Department of Public Health, AIDS Activities Coordinating Office
US* Philadelphia**
Number
87 Diagnosed
75 Are linked to HIV care
49 Stay in HIV care
48
Have a very low amount
of virus in their body
Number
93 Diagnosed
91 Are linked to HIV care
49 Stay in HIV care
52
Have a very low amount
of virus in their body
For every 100 people living with HIV:
*2013 Data **2015 Data
HIV PREVALENCE
Newly Diagnosed HIV Cases, Deaths, and Living HIV Cases by Year
Philadelphia, 2008-2015
928 897
739 694 737
634 569 538523 513 550 473 434 497
349 312
18640
19237
19525
19157
19832
19564 19494 19280
15000
16000
17000
18000
19000
20000
0
500
1000
1500
2000
2008 2009 2010 2011 2012 2013 2014 2015
Newly Diagnosed Deaths Living HIV Cases
Source: PDPH, AIDS Activities Coordinating Office, 2016
Rates of Adults and Adolescents Living with Diagnosed HIV Infection, by Area of
Residence, Year-end 2014 — United States and 6 Dependent Areas
N = 970,319 Total Rate: 360.0
Note. Data include persons with a diagnosis of HIV infection regardless of stage of disease at diagnosis. Data are based on address of residence as of
December 31, 2014 (i.e., most recent known address).
Persons Living with HIV/AIDS by Census Tract,
Philadelphia, 2015
Source: PDPH, AIDS Activities Coordinating Office, 2016
Comparison of HIV Prevalence in the
US and Philadelphia
Philadelphia EMA
• 26,807 PLWH as of 12/2015
– 482.6/100,000 population
– 1,263.4/100,000 in Philadelphia
• 57.9% black, 15.0% Latino, 22.8% white
• 70.9% male
• 48.8% current age >50 and 24.6% 40-49
• MSM – 35.5%, IDU – 21.3%,
Heterosexual – 34.8%
• Majority of cases among blacks,
regardless of risk
United States
• 955,081 as of 12/2014
– Rate 299.5/100,000 population
• 42.4% black, 20.8% Latino, 31.4%
white
• 75.6% male
• 44.9% current age >50 and 27.6%
40-49
• MSM – 53.3%, IDU – 13.7%,
Heterosexual – 25.8%
• Highest rates of HIV in the
Northeast US
Sources: PDPH, AIDS Activities Coordinating Office, 2016
https://www.cdc.gov/hiv/pdf/library/reports/surveillance/cdc-hiv-surveillance-report-2015-vol-27.pdf
Proportion of Philadelphia Residents Diagnosed and Living with HIV by
Race/Ethnicity and Sex, 2015
2.9%
2.3%
1.1% 1.1% 0.9%
0.2%
0.0%
1.0%
2.0%
3.0%
4.0%
5.0%
Black Males Hispanic
Males
Black
Females
White Males Hispanic
Females
White
Females
Overall Prevalence 1.3%
Epidemic Level 1.0%
Source: PDPH, AIDS Activities Coordinating Office, 2016
Proportion of Philadelphia EMA Residents Diagnosed
and Living with HIV by Race/Ethnicity and Sex, 2015
2.9%
2.3%
1.1% 1.1% 0.9%
0.2%
1.0%
0.6% 0.5% 0.1% 0.4%
0.0%
1.0% 0.8% 0.5% 0.2% 0.4%
0.0%
0.5%
1.0%
1.5%
2.0%
2.5%
3.0%
3.5%
Black Males Hispanic
Males
Black
Females
White Males Hispanic
Females
White
Females
Philly PA counties NJ Counties
HIV/AIDS Prevalence per 100,000 Population by Race
and Transmission Group, 2015
HIV DIAGNOSES
Newly Diagnosed HIV Cases, Deaths, and Living HIV Cases by Year
Philadelphia, 2008-2015
928 897
739 694 737
634 569 538523 513 550 473 434 497
349 312
18640
19237
19525
19157
19832
19564 19494 19280
15000
16000
17000
18000
19000
20000
0
500
1000
1500
2000
2008 2009 2010 2011 2012 2013 2014 2015
Newly Diagnosed Deaths Living HIV Cases
Source: PDPH, AIDS Activities Coordinating Office, 2016
Rates of Diagnoses of HIV Infection among Adults and Adolescents, by Area of
Residence, 2015 — United States and 6 Dependent Areas
N = 39,920 Total Rate: 14.7
Note. Data include persons with a diagnosis of HIV infection regardless of stage of disease at diagnosis. Data for the year 2015 are preliminary and based on 6
months reporting delay.
Persons Diagnosed with HIV (regardless of AIDS status)
by Census Tract, Philadelphia, 2015
Source: PDPH, AIDS Activities Coordinating Office, 2016
Newly Diagnosed HIV United States,
2014
• 44,073 estimated cases
• 80.7% male at birth
• 43.7% black, 24.3%
Hispanic, 26.9% white
• 22.0% among 13-24
year olds
66.5%
6.1%
24.1%
2.7%0.4%0.2%
Mode of Transmission
MSM IDU HET
MSM/IDU Pediatric NIR
Source: http://www.cdc.gov/hiv/pdf/library/reports/surveillance/cdc-hiv-
surveillance-report-us.pdf
Newly Diagnosed HIV Philadelphia,
2015
• 538 Newly Diagnosed
cases
• 78.0% male at birth
• 72.4% black, 14.1%
Hispanic, 10.4% white
• 25.0% among 13-24
year olds
56.5%
5.5%
35.1%
0.4%0.5% 2.0%
Mode of Transmission
MSM IDU HET
MSM/IDU Pediatric NIR
Source: PDPH, AIDS Activities Coordinating Office, 2016
Newly Diagnosed HIV Disease by Age at Diagnosis
(regardless of HIV status)
41 33
222
269
232
197 193
129
111
97 88
127 133
113 121
92
34
33
44
129
120147151
154
164
114
0
50
100
150
200
250
300
2010 2011 2012 2013 2014 2015
Year
NumberofCases
13-19 20-29 30-39 40-49 50+
Newly Diagnosed HIV Disease by Race/Ethnicity
(regardless of HIV status)
105 93
68
87
56
486
508
474
386 390
91
114
69 71 76
0
100
200
300
400
500
600
2010 2011 2012 2013 2014 2015
Year
NumberofCases
White AfrAm Hispanic
Newly Diagnosed HIV Disease by Sex at
Birth (regardless of AIDS status)
0
100
200
300
400
500
600
2010 2011 2012 2013 2014 2015
Year
NumberofCases
HIV Female HIV Male
41
Newly Diagnosed HIV Disease by Mode of
Transmission (regardless of AIDS status)
286
300
70
83
40 40 30
250
8 6 11
304
291
322
189
225
313313
30
9
0
50
100
150
200
250
300
350
2010 2011 2012 2013 2014 2015
Year
NumberofCases
MSM IDU HetSx NIR
Rates of Newly Diagnosed HIV/AIDS per 100,000
population, Philadelphia 2011-2015
Newly Diagnosed HIV (Non-AIDS) for
2015, Philadelphia EMA
EMA
Total
N=596
EMA
%
Phila
N=433
%
PA
N=85
%
NJ
N=78
%
Race/Ethnicity
White, non-Hispanic 98 16.4 10.6 42.4 20.5
Black, non-Hispanic 399 66.9 72.1 48.2 59.0
Hispanic 87 14.6 15.2 8.2 17.9
Asian/Pacific Islander 7 1.2 1.4 1.2 0.0
American Indian/Alaskan
Native
<6 0.2 0.2 0.0 0.0
Multi-Race <6 0.3 0.5 0.0 0.0
Gender
Male 449 70.2 75.5 72.9 76.9
Newly Diagnosed HIV (Non-AIDS) for
2015, Philadelphia EMA
EMA
Total
N=596
EMA
%
Phila
N=433
%
PA
N=85
%
NJ
N=78
%
Age
<13 years <6 0.3 0.8 0.0 0.0
13 - 19 years 38 6.4 7.6 2.4 3.8
20-24 years 128 21.5 22.2 16.5 23.1
25-29 years 121 20.3 18.7 18.8 30.8
30-39 years 127 21.3 23.3 15.3 16.7
40-49 years 79 13.3 13.2 17.6 9.0
50+ years 101 16.9 14.5 29.4 16.7
Newly Diagnosed HIV (Non-AIDS) for
2015, Philadelphia EMA
EMA
Total
N=596
EMA
%
Phila
N=433
%
PA
N=85
%
NJ
N=78
%
Mode of Transmission
Men who have sex with men
(MSM)
326 54.7 58.4 44.7 4.9
Injection drug users (IDU) 39 6.5 6.2 5.9 9.0
MSM/IDU <6 0.3 0.2 1.2 0.0
Heterosexuals 207 34.7 32.8 41.2 38.5
Other/hemophilia/blood
transfusion
0 0.0 0.0 0.0 0.0
Perinatal exposures <6 0.7 0.5 0.0 0.0
Risk not reported or identified 20 5.0 1.8 7.1 7.7
HIV INCIDENCE
2014 Local Estimate of
HIV Incidence
• Local estimate of 299 new HIV infections in
2014 in adults and adolescents (95% CI, 205-
393)
• Significant reduction since 2012
– 618 estimated HIV infections (95% CI, 419-817)
Source: PDPH, AIDS Activities Coordinating Office, 2016
HIV Incidence Trends by Demographic
Groups
0
200
400
600
800
1000
1200
2006 2007 2008 2009 2011 2012 2013 2014
Total Age 13-24 Male Black MSM
Source: PDPH, AIDS Activities Coordinating Office, 2016
Estimated Incidence Rates - 2014
Population Population in 2010
(13 +)
ESTIMATED
Incidence
Estimate,
2014
Estimated
Case Rate per
100,000
95% CI
lower
bound
95% CI
upper
bound
MSM 233,550 196 584.2 363.6 801.8
IDU 26,400 33 125.0 22.7 223.5
HET 269,231* 70 26.0 12.3 39.7
*Includes persons >13 living in poverty
Data Source: PDPH/AACO HIV Incidence Surveillance Program, 2016
SPECIAL POPULATIONS
Annual Retention, Annual Viral Suppression, and Durable
Viral Suppression by Ryan White Care, 2010-2014
52.8
63.3
46
19.2
27.8
20.4
0
20
40
60
80
100
Annual Retention
in Care*
Annual Viral
Suppression*
Durable Viral
Suppression*
Percent(%)
Ryan White
Non-Ryan White
*p<0.0001
Source: Philadelphia Department of Public Health, 2016
Philadelphia HIV Care Continuum 2015
0%
20%
40%
60%
80%
100%
Diagnosed Linked In Care Retained in
Care
Prescribed
ART
Virally
Suppressed
ALL PLWHA MSM of Color AA Men
Youth 13-24 AA Women Transgender
Source: PDPH, AIDS Activities Coordinating Office, 2016
Philadelphia HIV Care Continuum 2015
0%
20%
40%
60%
80%
100%
ALL PLWHA MSM of
Color
AA Men Youth 13-24 AA Women Transgender
Diagnosed Linked In Care
Retained in Care Prescribed ART Virally Suppressed
Source: PDPH, AIDS Activities Coordinating Office, 2016
Questions

More Related Content

What's hot

Using Data to Improve Linkage to Care
Using Data to Improve Linkage to CareUsing Data to Improve Linkage to Care
Using Data to Improve Linkage to Care
Randi Sylve
 
Anton Pozniak: "The Test and Treat Approach: Achieving 90-90-90"
Anton Pozniak: "The Test and Treat Approach: Achieving 90-90-90"Anton Pozniak: "The Test and Treat Approach: Achieving 90-90-90"
Anton Pozniak: "The Test and Treat Approach: Achieving 90-90-90"
HopkinsCFAR
 
The Kenya HIV Testing Services Guidelines 2015
The Kenya HIV Testing Services Guidelines 2015The Kenya HIV Testing Services Guidelines 2015
The Kenya HIV Testing Services Guidelines 2015
Cheryl Johnson
 
Epidemiological Update 2017 (Positive Committee)
Epidemiological Update 2017 (Positive Committee)Epidemiological Update 2017 (Positive Committee)
Epidemiological Update 2017 (Positive Committee)
Office of HIV Planning
 
Why, when, and how to use pre exposure prophylaxis for hiv acquisition. 2014
Why, when, and how to use pre exposure prophylaxis for hiv acquisition. 2014Why, when, and how to use pre exposure prophylaxis for hiv acquisition. 2014
Why, when, and how to use pre exposure prophylaxis for hiv acquisition. 2014
Hivlife Info
 
PrEP: Pre-exposure Prophylaxis
PrEP: Pre-exposure ProphylaxisPrEP: Pre-exposure Prophylaxis
Prevention in Her Hands: Findings from a PrEP Demonstration Study of Cisgende...
Prevention in Her Hands: Findings from a PrEP Demonstration Study of Cisgende...Prevention in Her Hands: Findings from a PrEP Demonstration Study of Cisgende...
Prevention in Her Hands: Findings from a PrEP Demonstration Study of Cisgende...
UC San Diego AntiViral Research Center
 
control of HIV AIDS infection 1.pptx
control of HIV AIDS infection        1.pptxcontrol of HIV AIDS infection        1.pptx
control of HIV AIDS infection 1.pptx
AleinaAli1
 
HIV self-testing and linkage in Africa
HIV self-testing and linkage in AfricaHIV self-testing and linkage in Africa
HIV self-testing and linkage in Africa
Cheryl Johnson
 
PrEP: Research update and implementation program in NSW
PrEP: Research update and implementation program in NSWPrEP: Research update and implementation program in NSW
PrEP: Research update and implementation program in NSW
Australian Federation of AIDS Organisations
 
What is epidemic control after 2020 mwango 04082021
What is epidemic control after 2020 mwango 04082021What is epidemic control after 2020 mwango 04082021
What is epidemic control after 2020 mwango 04082021
Albert Mwango
 
What is HIV epidemic control?
What is HIV epidemic control?What is HIV epidemic control?
What is HIV epidemic control?
Albert Mwango
 
Epidemiology Update: Disparities in the HIV Continuum of Care
Epidemiology Update: Disparities in the HIV Continuum of CareEpidemiology Update: Disparities in the HIV Continuum of Care
Epidemiology Update: Disparities in the HIV Continuum of Care
Office of HIV Planning
 
01 viral load testing in zambia
01 viral load testing in zambia01 viral load testing in zambia
01 viral load testing in zambia
Albert Mwango
 
03 children's enhanced adherence couselling in zambia ss
03 children's enhanced adherence couselling in zambia ss03 children's enhanced adherence couselling in zambia ss
03 children's enhanced adherence couselling in zambia ss
Albert Mwango
 
PEPFAR Programs
PEPFAR ProgramsPEPFAR Programs
06.11.21 | Practical Aspects of Dealing with Weight Gain in People with HIV
06.11.21 | Practical Aspects of Dealing with Weight Gain in People with HIV06.11.21 | Practical Aspects of Dealing with Weight Gain in People with HIV
06.11.21 | Practical Aspects of Dealing with Weight Gain in People with HIV
UC San Diego AntiViral Research Center
 
02 efficacious arv regimens for children in zambia
02 efficacious arv regimens for children in zambia02 efficacious arv regimens for children in zambia
02 efficacious arv regimens for children in zambia
Albert Mwango
 
Anza Sasa GUIDELINES 2016
Anza Sasa GUIDELINES 2016Anza Sasa GUIDELINES 2016
Anza Sasa GUIDELINES 2016
Donald Ogalo
 
NYSDOH AI PrEP for HIV Prevention
NYSDOH AI PrEP for HIV PreventionNYSDOH AI PrEP for HIV Prevention
NYSDOH AI PrEP for HIV Prevention
HIV Clinical Guidelines Program
 

What's hot (20)

Using Data to Improve Linkage to Care
Using Data to Improve Linkage to CareUsing Data to Improve Linkage to Care
Using Data to Improve Linkage to Care
 
Anton Pozniak: "The Test and Treat Approach: Achieving 90-90-90"
Anton Pozniak: "The Test and Treat Approach: Achieving 90-90-90"Anton Pozniak: "The Test and Treat Approach: Achieving 90-90-90"
Anton Pozniak: "The Test and Treat Approach: Achieving 90-90-90"
 
The Kenya HIV Testing Services Guidelines 2015
The Kenya HIV Testing Services Guidelines 2015The Kenya HIV Testing Services Guidelines 2015
The Kenya HIV Testing Services Guidelines 2015
 
Epidemiological Update 2017 (Positive Committee)
Epidemiological Update 2017 (Positive Committee)Epidemiological Update 2017 (Positive Committee)
Epidemiological Update 2017 (Positive Committee)
 
Why, when, and how to use pre exposure prophylaxis for hiv acquisition. 2014
Why, when, and how to use pre exposure prophylaxis for hiv acquisition. 2014Why, when, and how to use pre exposure prophylaxis for hiv acquisition. 2014
Why, when, and how to use pre exposure prophylaxis for hiv acquisition. 2014
 
PrEP: Pre-exposure Prophylaxis
PrEP: Pre-exposure ProphylaxisPrEP: Pre-exposure Prophylaxis
PrEP: Pre-exposure Prophylaxis
 
Prevention in Her Hands: Findings from a PrEP Demonstration Study of Cisgende...
Prevention in Her Hands: Findings from a PrEP Demonstration Study of Cisgende...Prevention in Her Hands: Findings from a PrEP Demonstration Study of Cisgende...
Prevention in Her Hands: Findings from a PrEP Demonstration Study of Cisgende...
 
control of HIV AIDS infection 1.pptx
control of HIV AIDS infection        1.pptxcontrol of HIV AIDS infection        1.pptx
control of HIV AIDS infection 1.pptx
 
HIV self-testing and linkage in Africa
HIV self-testing and linkage in AfricaHIV self-testing and linkage in Africa
HIV self-testing and linkage in Africa
 
PrEP: Research update and implementation program in NSW
PrEP: Research update and implementation program in NSWPrEP: Research update and implementation program in NSW
PrEP: Research update and implementation program in NSW
 
What is epidemic control after 2020 mwango 04082021
What is epidemic control after 2020 mwango 04082021What is epidemic control after 2020 mwango 04082021
What is epidemic control after 2020 mwango 04082021
 
What is HIV epidemic control?
What is HIV epidemic control?What is HIV epidemic control?
What is HIV epidemic control?
 
Epidemiology Update: Disparities in the HIV Continuum of Care
Epidemiology Update: Disparities in the HIV Continuum of CareEpidemiology Update: Disparities in the HIV Continuum of Care
Epidemiology Update: Disparities in the HIV Continuum of Care
 
01 viral load testing in zambia
01 viral load testing in zambia01 viral load testing in zambia
01 viral load testing in zambia
 
03 children's enhanced adherence couselling in zambia ss
03 children's enhanced adherence couselling in zambia ss03 children's enhanced adherence couselling in zambia ss
03 children's enhanced adherence couselling in zambia ss
 
PEPFAR Programs
PEPFAR ProgramsPEPFAR Programs
PEPFAR Programs
 
06.11.21 | Practical Aspects of Dealing with Weight Gain in People with HIV
06.11.21 | Practical Aspects of Dealing with Weight Gain in People with HIV06.11.21 | Practical Aspects of Dealing with Weight Gain in People with HIV
06.11.21 | Practical Aspects of Dealing with Weight Gain in People with HIV
 
02 efficacious arv regimens for children in zambia
02 efficacious arv regimens for children in zambia02 efficacious arv regimens for children in zambia
02 efficacious arv regimens for children in zambia
 
Anza Sasa GUIDELINES 2016
Anza Sasa GUIDELINES 2016Anza Sasa GUIDELINES 2016
Anza Sasa GUIDELINES 2016
 
NYSDOH AI PrEP for HIV Prevention
NYSDOH AI PrEP for HIV PreventionNYSDOH AI PrEP for HIV Prevention
NYSDOH AI PrEP for HIV Prevention
 

Viewers also liked

Medicaid, Medicare, and ACA Insurance Plans
Medicaid, Medicare, and ACA Insurance PlansMedicaid, Medicare, and ACA Insurance Plans
Medicaid, Medicare, and ACA Insurance Plans
Office of HIV Planning
 
RWPC Primer
RWPC PrimerRWPC Primer
Creative Arts Therapies at Parkway Health and Wellness
Creative Arts Therapies at Parkway Health and WellnessCreative Arts Therapies at Parkway Health and Wellness
Creative Arts Therapies at Parkway Health and Wellness
Office of HIV Planning
 
Working Toward Eradication (Hepatitis C/HIV Coinfection Presentation) - Alex ...
Working Toward Eradication (Hepatitis C/HIV Coinfection Presentation) - Alex ...Working Toward Eradication (Hepatitis C/HIV Coinfection Presentation) - Alex ...
Working Toward Eradication (Hepatitis C/HIV Coinfection Presentation) - Alex ...
Office of HIV Planning
 
Integrated Planning Process Review, 2016
Integrated Planning Process Review, 2016Integrated Planning Process Review, 2016
Integrated Planning Process Review, 2016
Office of HIV Planning
 
Health Insurance Premium and Cost Sharing Assistance
Health Insurance Premium and Cost Sharing AssistanceHealth Insurance Premium and Cost Sharing Assistance
Health Insurance Premium and Cost Sharing Assistance
Office of HIV Planning
 
Kathleen Brady - HIV in Philadelphia (Annual Epidemiological Presentation)
Kathleen Brady - HIV in Philadelphia (Annual Epidemiological Presentation)Kathleen Brady - HIV in Philadelphia (Annual Epidemiological Presentation)
Kathleen Brady - HIV in Philadelphia (Annual Epidemiological Presentation)
Office of HIV Planning
 
AACO Client Services Presentation
AACO Client Services PresentationAACO Client Services Presentation
AACO Client Services Presentation
Office of HIV Planning
 
Kathleen Brady Philadelphia HIV Epidemiologic Update 2015
Kathleen Brady Philadelphia HIV Epidemiologic Update 2015Kathleen Brady Philadelphia HIV Epidemiologic Update 2015
Kathleen Brady Philadelphia HIV Epidemiologic Update 2015
Office of HIV Planning
 
It’s Time for PrEP (Kathleen Brady, Philadelphia Department of Public Health)
It’s Time for PrEP (Kathleen Brady, Philadelphia Department of Public Health)It’s Time for PrEP (Kathleen Brady, Philadelphia Department of Public Health)
It’s Time for PrEP (Kathleen Brady, Philadelphia Department of Public Health)
Office of HIV Planning
 
2014 Epidemiological Update by Dr. Kathleen Brady
2014 Epidemiological Update by Dr. Kathleen Brady2014 Epidemiological Update by Dr. Kathleen Brady
2014 Epidemiological Update by Dr. Kathleen Brady
Office of HIV Planning
 
Youth Risk Behavior Survey 2016 by Dr. Anne Frankel
Youth Risk Behavior Survey 2016 by Dr. Anne FrankelYouth Risk Behavior Survey 2016 by Dr. Anne Frankel
Youth Risk Behavior Survey 2016 by Dr. Anne Frankel
Office of HIV Planning
 
Youth Risk Behavior Survey Presentation, Antonio Boone
Youth Risk Behavior Survey Presentation, Antonio BooneYouth Risk Behavior Survey Presentation, Antonio Boone
Youth Risk Behavior Survey Presentation, Antonio Boone
Office of HIV Planning
 
AACO Annual Client Services Unit (CSU) Report
AACO Annual Client Services Unit (CSU) ReportAACO Annual Client Services Unit (CSU) Report
AACO Annual Client Services Unit (CSU) Report
Office of HIV Planning
 
Filosofia (1)
Filosofia (1)Filosofia (1)
Filosofia (1)
gabriela linares
 
Construcción de-la-identidadklkl
Construcción de-la-identidadklklConstrucción de-la-identidadklkl
Construcción de-la-identidadklkl
gabriela linares
 
Construcción de-la-identidadklkl
Construcción de-la-identidadklklConstrucción de-la-identidadklkl
Construcción de-la-identidadklkl
gabriela linares
 
Linea de tiempo personal
Linea de tiempo personalLinea de tiempo personal
Linea de tiempo personal
gabriela linares
 
Linea de tiempo personal
Linea de tiempo personalLinea de tiempo personal
Linea de tiempo personal
gabriela linares
 
Social work in uganda
Social work in ugandaSocial work in uganda
Social work in uganda
kitimbo stanley
 

Viewers also liked (20)

Medicaid, Medicare, and ACA Insurance Plans
Medicaid, Medicare, and ACA Insurance PlansMedicaid, Medicare, and ACA Insurance Plans
Medicaid, Medicare, and ACA Insurance Plans
 
RWPC Primer
RWPC PrimerRWPC Primer
RWPC Primer
 
Creative Arts Therapies at Parkway Health and Wellness
Creative Arts Therapies at Parkway Health and WellnessCreative Arts Therapies at Parkway Health and Wellness
Creative Arts Therapies at Parkway Health and Wellness
 
Working Toward Eradication (Hepatitis C/HIV Coinfection Presentation) - Alex ...
Working Toward Eradication (Hepatitis C/HIV Coinfection Presentation) - Alex ...Working Toward Eradication (Hepatitis C/HIV Coinfection Presentation) - Alex ...
Working Toward Eradication (Hepatitis C/HIV Coinfection Presentation) - Alex ...
 
Integrated Planning Process Review, 2016
Integrated Planning Process Review, 2016Integrated Planning Process Review, 2016
Integrated Planning Process Review, 2016
 
Health Insurance Premium and Cost Sharing Assistance
Health Insurance Premium and Cost Sharing AssistanceHealth Insurance Premium and Cost Sharing Assistance
Health Insurance Premium and Cost Sharing Assistance
 
Kathleen Brady - HIV in Philadelphia (Annual Epidemiological Presentation)
Kathleen Brady - HIV in Philadelphia (Annual Epidemiological Presentation)Kathleen Brady - HIV in Philadelphia (Annual Epidemiological Presentation)
Kathleen Brady - HIV in Philadelphia (Annual Epidemiological Presentation)
 
AACO Client Services Presentation
AACO Client Services PresentationAACO Client Services Presentation
AACO Client Services Presentation
 
Kathleen Brady Philadelphia HIV Epidemiologic Update 2015
Kathleen Brady Philadelphia HIV Epidemiologic Update 2015Kathleen Brady Philadelphia HIV Epidemiologic Update 2015
Kathleen Brady Philadelphia HIV Epidemiologic Update 2015
 
It’s Time for PrEP (Kathleen Brady, Philadelphia Department of Public Health)
It’s Time for PrEP (Kathleen Brady, Philadelphia Department of Public Health)It’s Time for PrEP (Kathleen Brady, Philadelphia Department of Public Health)
It’s Time for PrEP (Kathleen Brady, Philadelphia Department of Public Health)
 
2014 Epidemiological Update by Dr. Kathleen Brady
2014 Epidemiological Update by Dr. Kathleen Brady2014 Epidemiological Update by Dr. Kathleen Brady
2014 Epidemiological Update by Dr. Kathleen Brady
 
Youth Risk Behavior Survey 2016 by Dr. Anne Frankel
Youth Risk Behavior Survey 2016 by Dr. Anne FrankelYouth Risk Behavior Survey 2016 by Dr. Anne Frankel
Youth Risk Behavior Survey 2016 by Dr. Anne Frankel
 
Youth Risk Behavior Survey Presentation, Antonio Boone
Youth Risk Behavior Survey Presentation, Antonio BooneYouth Risk Behavior Survey Presentation, Antonio Boone
Youth Risk Behavior Survey Presentation, Antonio Boone
 
AACO Annual Client Services Unit (CSU) Report
AACO Annual Client Services Unit (CSU) ReportAACO Annual Client Services Unit (CSU) Report
AACO Annual Client Services Unit (CSU) Report
 
Filosofia (1)
Filosofia (1)Filosofia (1)
Filosofia (1)
 
Construcción de-la-identidadklkl
Construcción de-la-identidadklklConstrucción de-la-identidadklkl
Construcción de-la-identidadklkl
 
Construcción de-la-identidadklkl
Construcción de-la-identidadklklConstrucción de-la-identidadklkl
Construcción de-la-identidadklkl
 
Linea de tiempo personal
Linea de tiempo personalLinea de tiempo personal
Linea de tiempo personal
 
Linea de tiempo personal
Linea de tiempo personalLinea de tiempo personal
Linea de tiempo personal
 
Social work in uganda
Social work in ugandaSocial work in uganda
Social work in uganda
 

Similar to Annual Epidemiological Presentation, 2017 - Kathleen Brady, PDPH

2014 Epidemiological Update by Dr. Kathleen Brady
2014 Epidemiological Update by Dr. Kathleen Brady2014 Epidemiological Update by Dr. Kathleen Brady
2014 Epidemiological Update by Dr. Kathleen Brady
Office of HIV Planning
 
Dr. Kathleen Brady's 2013 Epidemiologic Update
Dr. Kathleen Brady's 2013 Epidemiologic UpdateDr. Kathleen Brady's 2013 Epidemiologic Update
Dr. Kathleen Brady's 2013 Epidemiologic Update
Office of HIV Planning
 
The HIV Engagement in Care Cascade by Dr. Kathleen Brady
The HIV Engagement in Care Cascade by Dr. Kathleen BradyThe HIV Engagement in Care Cascade by Dr. Kathleen Brady
The HIV Engagement in Care Cascade by Dr. Kathleen Brady
Office of HIV Planning
 
Barriers of HIV Prevention through Treatment
Barriers of HIV Prevention through TreatmentBarriers of HIV Prevention through Treatment
Barriers of HIV Prevention through Treatment
UC San Diego AntiViral Research Center
 
Chris Beyrer: "State of the Science: Key populations"
Chris Beyrer: "State of the Science: Key populations"Chris Beyrer: "State of the Science: Key populations"
Chris Beyrer: "State of the Science: Key populations"
HopkinsCFAR
 
Where are we on HIV testing services - the achievements and the gaps
Where are we on HIV testing services - the achievements and the gapsWhere are we on HIV testing services - the achievements and the gaps
Where are we on HIV testing services - the achievements and the gaps
Cheryl Johnson
 
Getting to scale: How we can achieve the reach required of prevention service...
Getting to scale: How we can achieve the reach required of prevention service...Getting to scale: How we can achieve the reach required of prevention service...
Getting to scale: How we can achieve the reach required of prevention service...
HopkinsCFAR
 
08.28.20 | Update on the Epidemiology of HCV Infection and National Screening...
08.28.20 | Update on the Epidemiology of HCV Infection and National Screening...08.28.20 | Update on the Epidemiology of HCV Infection and National Screening...
08.28.20 | Update on the Epidemiology of HCV Infection and National Screening...
UC San Diego AntiViral Research Center
 
Test and Treat: The Gardner Cascade in Context
Test and Treat: The Gardner Cascade in ContextTest and Treat: The Gardner Cascade in Context
Test and Treat: The Gardner Cascade in Context
Office of HIV Planning
 
HIV: NEW PUBLIC HEALTH INTERVENTIONS
HIV: NEW PUBLIC HEALTH INTERVENTIONSHIV: NEW PUBLIC HEALTH INTERVENTIONS
HIV: NEW PUBLIC HEALTH INTERVENTIONS
UC San Diego AntiViral Research Center
 
Estimation of HIV incidence in Malawi from cross-sectional population-based s...
Estimation of HIV incidence in Malawi from cross-sectional population-based s...Estimation of HIV incidence in Malawi from cross-sectional population-based s...
Estimation of HIV incidence in Malawi from cross-sectional population-based s...
Humphrey Misiri
 
Estimation of HIV incidence in Malawi from cross-sectional population-based s...
Estimation of HIV incidence in Malawi from cross-sectional population-based s...Estimation of HIV incidence in Malawi from cross-sectional population-based s...
Estimation of HIV incidence in Malawi from cross-sectional population-based s...
Humphrey Misiri
 
Hiv eye update 2013
Hiv eye update 2013Hiv eye update 2013
Hiv eye update 2013
etedaldi
 
Health System Navigators Presentation
Health System Navigators PresentationHealth System Navigators Presentation
Health System Navigators Presentation
Office of HIV Planning
 
Health System Navigators Presentation
Health System Navigators PresentationHealth System Navigators Presentation
Health System Navigators Presentation
Office of HIV Planning
 
HIV Winnable Battle presentation
HIV Winnable Battle presentationHIV Winnable Battle presentation
HIV Winnable Battle presentation
PublicHealthFoundation
 
Using Data to Improve LTC - Debbie Wendell
Using Data to Improve LTC -  Debbie WendellUsing Data to Improve LTC -  Debbie Wendell
Using Data to Improve LTC - Debbie Wendell
Louisiana STD/HIV Program (LAOPH/SHP)
 
Importance of HIV testing and linkage to care
Importance of HIV testing and linkage to careImportance of HIV testing and linkage to care
Importance of HIV testing and linkage to care
European Centre for Disease Prevention and Control
 
HIV/AIDS
HIV/AIDSHIV/AIDS
HIV/AIDS
Pretty Nkosi
 
HIV/AIDS RECENT ADVANCES
HIV/AIDS RECENT ADVANCESHIV/AIDS RECENT ADVANCES
HIV/AIDS RECENT ADVANCES
Soumya Sahoo
 

Similar to Annual Epidemiological Presentation, 2017 - Kathleen Brady, PDPH (20)

2014 Epidemiological Update by Dr. Kathleen Brady
2014 Epidemiological Update by Dr. Kathleen Brady2014 Epidemiological Update by Dr. Kathleen Brady
2014 Epidemiological Update by Dr. Kathleen Brady
 
Dr. Kathleen Brady's 2013 Epidemiologic Update
Dr. Kathleen Brady's 2013 Epidemiologic UpdateDr. Kathleen Brady's 2013 Epidemiologic Update
Dr. Kathleen Brady's 2013 Epidemiologic Update
 
The HIV Engagement in Care Cascade by Dr. Kathleen Brady
The HIV Engagement in Care Cascade by Dr. Kathleen BradyThe HIV Engagement in Care Cascade by Dr. Kathleen Brady
The HIV Engagement in Care Cascade by Dr. Kathleen Brady
 
Barriers of HIV Prevention through Treatment
Barriers of HIV Prevention through TreatmentBarriers of HIV Prevention through Treatment
Barriers of HIV Prevention through Treatment
 
Chris Beyrer: "State of the Science: Key populations"
Chris Beyrer: "State of the Science: Key populations"Chris Beyrer: "State of the Science: Key populations"
Chris Beyrer: "State of the Science: Key populations"
 
Where are we on HIV testing services - the achievements and the gaps
Where are we on HIV testing services - the achievements and the gapsWhere are we on HIV testing services - the achievements and the gaps
Where are we on HIV testing services - the achievements and the gaps
 
Getting to scale: How we can achieve the reach required of prevention service...
Getting to scale: How we can achieve the reach required of prevention service...Getting to scale: How we can achieve the reach required of prevention service...
Getting to scale: How we can achieve the reach required of prevention service...
 
08.28.20 | Update on the Epidemiology of HCV Infection and National Screening...
08.28.20 | Update on the Epidemiology of HCV Infection and National Screening...08.28.20 | Update on the Epidemiology of HCV Infection and National Screening...
08.28.20 | Update on the Epidemiology of HCV Infection and National Screening...
 
Test and Treat: The Gardner Cascade in Context
Test and Treat: The Gardner Cascade in ContextTest and Treat: The Gardner Cascade in Context
Test and Treat: The Gardner Cascade in Context
 
HIV: NEW PUBLIC HEALTH INTERVENTIONS
HIV: NEW PUBLIC HEALTH INTERVENTIONSHIV: NEW PUBLIC HEALTH INTERVENTIONS
HIV: NEW PUBLIC HEALTH INTERVENTIONS
 
Estimation of HIV incidence in Malawi from cross-sectional population-based s...
Estimation of HIV incidence in Malawi from cross-sectional population-based s...Estimation of HIV incidence in Malawi from cross-sectional population-based s...
Estimation of HIV incidence in Malawi from cross-sectional population-based s...
 
Estimation of HIV incidence in Malawi from cross-sectional population-based s...
Estimation of HIV incidence in Malawi from cross-sectional population-based s...Estimation of HIV incidence in Malawi from cross-sectional population-based s...
Estimation of HIV incidence in Malawi from cross-sectional population-based s...
 
Hiv eye update 2013
Hiv eye update 2013Hiv eye update 2013
Hiv eye update 2013
 
Health System Navigators Presentation
Health System Navigators PresentationHealth System Navigators Presentation
Health System Navigators Presentation
 
Health System Navigators Presentation
Health System Navigators PresentationHealth System Navigators Presentation
Health System Navigators Presentation
 
HIV Winnable Battle presentation
HIV Winnable Battle presentationHIV Winnable Battle presentation
HIV Winnable Battle presentation
 
Using Data to Improve LTC - Debbie Wendell
Using Data to Improve LTC -  Debbie WendellUsing Data to Improve LTC -  Debbie Wendell
Using Data to Improve LTC - Debbie Wendell
 
Importance of HIV testing and linkage to care
Importance of HIV testing and linkage to careImportance of HIV testing and linkage to care
Importance of HIV testing and linkage to care
 
HIV/AIDS
HIV/AIDSHIV/AIDS
HIV/AIDS
 
HIV/AIDS RECENT ADVANCES
HIV/AIDS RECENT ADVANCESHIV/AIDS RECENT ADVANCES
HIV/AIDS RECENT ADVANCES
 

More from Office of HIV Planning

Overview of the 2018 Update to the Integrated Plan and PrEP Workgroup Draft R...
Overview of the 2018 Update to the Integrated Plan and PrEP Workgroup Draft R...Overview of the 2018 Update to the Integrated Plan and PrEP Workgroup Draft R...
Overview of the 2018 Update to the Integrated Plan and PrEP Workgroup Draft R...
Office of HIV Planning
 
PrEP Update: CROI 2018
PrEP Update: CROI 2018PrEP Update: CROI 2018
PrEP Update: CROI 2018
Office of HIV Planning
 
Quality Management in the Philadelphia EMA
Quality Management in the Philadelphia EMAQuality Management in the Philadelphia EMA
Quality Management in the Philadelphia EMA
Office of HIV Planning
 
C-YA! Philadelphia EMA's Plan to Connect our Co-infected Community to a Cure ...
C-YA! Philadelphia EMA's Plan to Connect our Co-infected Community to a Cure ...C-YA! Philadelphia EMA's Plan to Connect our Co-infected Community to a Cure ...
C-YA! Philadelphia EMA's Plan to Connect our Co-infected Community to a Cure ...
Office of HIV Planning
 
Client Services Unit Update 2018
Client Services Unit Update 2018Client Services Unit Update 2018
Client Services Unit Update 2018
Office of HIV Planning
 
Epidemiologic Profile Preview
Epidemiologic Profile PreviewEpidemiologic Profile Preview
Epidemiologic Profile Preview
Office of HIV Planning
 
Increasing Treatment Access and Saving Lives in the Dual Opioid and Overdose ...
Increasing Treatment Access and Saving Lives in the Dual Opioid and Overdose ...Increasing Treatment Access and Saving Lives in the Dual Opioid and Overdose ...
Increasing Treatment Access and Saving Lives in the Dual Opioid and Overdose ...
Office of HIV Planning
 
Philadelphia National HIV Behavioral Surveillance, 2018
Philadelphia National HIV Behavioral Surveillance, 2018Philadelphia National HIV Behavioral Surveillance, 2018
Philadelphia National HIV Behavioral Surveillance, 2018
Office of HIV Planning
 
Safer Consumption Spaces
Safer Consumption SpacesSafer Consumption Spaces
Safer Consumption Spaces
Office of HIV Planning
 
Philadelphia PrEP Working Group
Philadelphia PrEP Working GroupPhiladelphia PrEP Working Group
Philadelphia PrEP Working Group
Office of HIV Planning
 
Opioid Awareness
Opioid AwarenessOpioid Awareness
Opioid Awareness
Office of HIV Planning
 
Being Trauma-Informed in the Care of People Living with HIV
Being Trauma-Informed in the Care of People Living with HIVBeing Trauma-Informed in the Care of People Living with HIV
Being Trauma-Informed in the Care of People Living with HIV
Office of HIV Planning
 
Prevention Continuum
Prevention ContinuumPrevention Continuum
Prevention Continuum
Office of HIV Planning
 
Integrated HIV Surveillance and Prevention Programs for Health Departments - ...
Integrated HIV Surveillance and Prevention Programs for Health Departments - ...Integrated HIV Surveillance and Prevention Programs for Health Departments - ...
Integrated HIV Surveillance and Prevention Programs for Health Departments - ...
Office of HIV Planning
 
BenePhilly Programs Presentation
BenePhilly Programs PresentationBenePhilly Programs Presentation
BenePhilly Programs Presentation
Office of HIV Planning
 
Future Directions In Medical Case Management
Future Directions In Medical Case ManagementFuture Directions In Medical Case Management
Future Directions In Medical Case Management
Office of HIV Planning
 
Opioid Awareness - Report Review: The Mayor's Task Force to Combat the Opioid...
Opioid Awareness - Report Review: The Mayor's Task Force to Combat the Opioid...Opioid Awareness - Report Review: The Mayor's Task Force to Combat the Opioid...
Opioid Awareness - Report Review: The Mayor's Task Force to Combat the Opioid...
Office of HIV Planning
 
Treatment Update - Modernizing the HIV Care Delivery Model
Treatment Update - Modernizing the HIV Care Delivery ModelTreatment Update - Modernizing the HIV Care Delivery Model
Treatment Update - Modernizing the HIV Care Delivery Model
Office of HIV Planning
 
What is Integrated Planning?
What is Integrated Planning?What is Integrated Planning?
What is Integrated Planning?
Office of HIV Planning
 
Ryan White HIV AIDS Program (RWHAP) Services and Policy Clarification Notice ...
Ryan White HIV AIDS Program (RWHAP) Services and Policy Clarification Notice ...Ryan White HIV AIDS Program (RWHAP) Services and Policy Clarification Notice ...
Ryan White HIV AIDS Program (RWHAP) Services and Policy Clarification Notice ...
Office of HIV Planning
 

More from Office of HIV Planning (20)

Overview of the 2018 Update to the Integrated Plan and PrEP Workgroup Draft R...
Overview of the 2018 Update to the Integrated Plan and PrEP Workgroup Draft R...Overview of the 2018 Update to the Integrated Plan and PrEP Workgroup Draft R...
Overview of the 2018 Update to the Integrated Plan and PrEP Workgroup Draft R...
 
PrEP Update: CROI 2018
PrEP Update: CROI 2018PrEP Update: CROI 2018
PrEP Update: CROI 2018
 
Quality Management in the Philadelphia EMA
Quality Management in the Philadelphia EMAQuality Management in the Philadelphia EMA
Quality Management in the Philadelphia EMA
 
C-YA! Philadelphia EMA's Plan to Connect our Co-infected Community to a Cure ...
C-YA! Philadelphia EMA's Plan to Connect our Co-infected Community to a Cure ...C-YA! Philadelphia EMA's Plan to Connect our Co-infected Community to a Cure ...
C-YA! Philadelphia EMA's Plan to Connect our Co-infected Community to a Cure ...
 
Client Services Unit Update 2018
Client Services Unit Update 2018Client Services Unit Update 2018
Client Services Unit Update 2018
 
Epidemiologic Profile Preview
Epidemiologic Profile PreviewEpidemiologic Profile Preview
Epidemiologic Profile Preview
 
Increasing Treatment Access and Saving Lives in the Dual Opioid and Overdose ...
Increasing Treatment Access and Saving Lives in the Dual Opioid and Overdose ...Increasing Treatment Access and Saving Lives in the Dual Opioid and Overdose ...
Increasing Treatment Access and Saving Lives in the Dual Opioid and Overdose ...
 
Philadelphia National HIV Behavioral Surveillance, 2018
Philadelphia National HIV Behavioral Surveillance, 2018Philadelphia National HIV Behavioral Surveillance, 2018
Philadelphia National HIV Behavioral Surveillance, 2018
 
Safer Consumption Spaces
Safer Consumption SpacesSafer Consumption Spaces
Safer Consumption Spaces
 
Philadelphia PrEP Working Group
Philadelphia PrEP Working GroupPhiladelphia PrEP Working Group
Philadelphia PrEP Working Group
 
Opioid Awareness
Opioid AwarenessOpioid Awareness
Opioid Awareness
 
Being Trauma-Informed in the Care of People Living with HIV
Being Trauma-Informed in the Care of People Living with HIVBeing Trauma-Informed in the Care of People Living with HIV
Being Trauma-Informed in the Care of People Living with HIV
 
Prevention Continuum
Prevention ContinuumPrevention Continuum
Prevention Continuum
 
Integrated HIV Surveillance and Prevention Programs for Health Departments - ...
Integrated HIV Surveillance and Prevention Programs for Health Departments - ...Integrated HIV Surveillance and Prevention Programs for Health Departments - ...
Integrated HIV Surveillance and Prevention Programs for Health Departments - ...
 
BenePhilly Programs Presentation
BenePhilly Programs PresentationBenePhilly Programs Presentation
BenePhilly Programs Presentation
 
Future Directions In Medical Case Management
Future Directions In Medical Case ManagementFuture Directions In Medical Case Management
Future Directions In Medical Case Management
 
Opioid Awareness - Report Review: The Mayor's Task Force to Combat the Opioid...
Opioid Awareness - Report Review: The Mayor's Task Force to Combat the Opioid...Opioid Awareness - Report Review: The Mayor's Task Force to Combat the Opioid...
Opioid Awareness - Report Review: The Mayor's Task Force to Combat the Opioid...
 
Treatment Update - Modernizing the HIV Care Delivery Model
Treatment Update - Modernizing the HIV Care Delivery ModelTreatment Update - Modernizing the HIV Care Delivery Model
Treatment Update - Modernizing the HIV Care Delivery Model
 
What is Integrated Planning?
What is Integrated Planning?What is Integrated Planning?
What is Integrated Planning?
 
Ryan White HIV AIDS Program (RWHAP) Services and Policy Clarification Notice ...
Ryan White HIV AIDS Program (RWHAP) Services and Policy Clarification Notice ...Ryan White HIV AIDS Program (RWHAP) Services and Policy Clarification Notice ...
Ryan White HIV AIDS Program (RWHAP) Services and Policy Clarification Notice ...
 

Recently uploaded

Netter's Atlas of Human Anatomy 7.ed.pdf
Netter's Atlas of Human Anatomy 7.ed.pdfNetter's Atlas of Human Anatomy 7.ed.pdf
Netter's Atlas of Human Anatomy 7.ed.pdf
BrissaOrtiz3
 
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.GawadHemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
NephroTube - Dr.Gawad
 
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
rishi2789
 
Chapter 11 Nutrition and Chronic Diseases.pptx
Chapter 11 Nutrition and Chronic Diseases.pptxChapter 11 Nutrition and Chronic Diseases.pptx
Chapter 11 Nutrition and Chronic Diseases.pptx
Earlene McNair
 
TEST BANK For Basic and Clinical Pharmacology, 14th Edition by Bertram G. Kat...
TEST BANK For Basic and Clinical Pharmacology, 14th Edition by Bertram G. Kat...TEST BANK For Basic and Clinical Pharmacology, 14th Edition by Bertram G. Kat...
TEST BANK For Basic and Clinical Pharmacology, 14th Edition by Bertram G. Kat...
rightmanforbloodline
 
Muscles of Mastication by Dr. Rabia Inam Gandapore.pptx
Muscles of Mastication by Dr. Rabia Inam Gandapore.pptxMuscles of Mastication by Dr. Rabia Inam Gandapore.pptx
Muscles of Mastication by Dr. Rabia Inam Gandapore.pptx
Dr. Rabia Inam Gandapore
 
Efficacy of Avartana Sneha in Ayurveda
Efficacy of Avartana Sneha in AyurvedaEfficacy of Avartana Sneha in Ayurveda
Efficacy of Avartana Sneha in Ayurveda
Dr. Jyothirmai Paindla
 
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptxREGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
LaniyaNasrink
 
CBL Seminar 2024_Preliminary Program.pdf
CBL Seminar 2024_Preliminary Program.pdfCBL Seminar 2024_Preliminary Program.pdf
CBL Seminar 2024_Preliminary Program.pdf
suvadeepdas911
 
TEST BANK For An Introduction to Brain and Behavior, 7th Edition by Bryan Kol...
TEST BANK For An Introduction to Brain and Behavior, 7th Edition by Bryan Kol...TEST BANK For An Introduction to Brain and Behavior, 7th Edition by Bryan Kol...
TEST BANK For An Introduction to Brain and Behavior, 7th Edition by Bryan Kol...
rightmanforbloodline
 
Journal Article Review on Rasamanikya
Journal Article Review on RasamanikyaJournal Article Review on Rasamanikya
Journal Article Review on Rasamanikya
Dr. Jyothirmai Paindla
 
Cardiac Assessment for B.sc Nursing Student.pdf
Cardiac Assessment for B.sc Nursing Student.pdfCardiac Assessment for B.sc Nursing Student.pdf
Cardiac Assessment for B.sc Nursing Student.pdf
shivalingatalekar1
 
Best Ayurvedic medicine for Gas and Indigestion
Best Ayurvedic medicine for Gas and IndigestionBest Ayurvedic medicine for Gas and Indigestion
Best Ayurvedic medicine for Gas and Indigestion
Swastik Ayurveda
 
Does Over-Masturbation Contribute to Chronic Prostatitis.pptx
Does Over-Masturbation Contribute to Chronic Prostatitis.pptxDoes Over-Masturbation Contribute to Chronic Prostatitis.pptx
Does Over-Masturbation Contribute to Chronic Prostatitis.pptx
walterHu5
 
A Classical Text Review on Basavarajeeyam
A Classical Text Review on BasavarajeeyamA Classical Text Review on Basavarajeeyam
A Classical Text Review on Basavarajeeyam
Dr. Jyothirmai Paindla
 
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptxEar and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
Dr. Rabia Inam Gandapore
 
Aortic Association CBL Pilot April 19 – 20 Bern
Aortic Association CBL Pilot April 19 – 20 BernAortic Association CBL Pilot April 19 – 20 Bern
Aortic Association CBL Pilot April 19 – 20 Bern
suvadeepdas911
 
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotesPromoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
PsychoTech Services
 
Tests for analysis of different pharmaceutical.pptx
Tests for analysis of different pharmaceutical.pptxTests for analysis of different pharmaceutical.pptx
Tests for analysis of different pharmaceutical.pptx
taiba qazi
 
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
Holistified Wellness
 

Recently uploaded (20)

Netter's Atlas of Human Anatomy 7.ed.pdf
Netter's Atlas of Human Anatomy 7.ed.pdfNetter's Atlas of Human Anatomy 7.ed.pdf
Netter's Atlas of Human Anatomy 7.ed.pdf
 
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.GawadHemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
 
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
 
Chapter 11 Nutrition and Chronic Diseases.pptx
Chapter 11 Nutrition and Chronic Diseases.pptxChapter 11 Nutrition and Chronic Diseases.pptx
Chapter 11 Nutrition and Chronic Diseases.pptx
 
TEST BANK For Basic and Clinical Pharmacology, 14th Edition by Bertram G. Kat...
TEST BANK For Basic and Clinical Pharmacology, 14th Edition by Bertram G. Kat...TEST BANK For Basic and Clinical Pharmacology, 14th Edition by Bertram G. Kat...
TEST BANK For Basic and Clinical Pharmacology, 14th Edition by Bertram G. Kat...
 
Muscles of Mastication by Dr. Rabia Inam Gandapore.pptx
Muscles of Mastication by Dr. Rabia Inam Gandapore.pptxMuscles of Mastication by Dr. Rabia Inam Gandapore.pptx
Muscles of Mastication by Dr. Rabia Inam Gandapore.pptx
 
Efficacy of Avartana Sneha in Ayurveda
Efficacy of Avartana Sneha in AyurvedaEfficacy of Avartana Sneha in Ayurveda
Efficacy of Avartana Sneha in Ayurveda
 
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptxREGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
 
CBL Seminar 2024_Preliminary Program.pdf
CBL Seminar 2024_Preliminary Program.pdfCBL Seminar 2024_Preliminary Program.pdf
CBL Seminar 2024_Preliminary Program.pdf
 
TEST BANK For An Introduction to Brain and Behavior, 7th Edition by Bryan Kol...
TEST BANK For An Introduction to Brain and Behavior, 7th Edition by Bryan Kol...TEST BANK For An Introduction to Brain and Behavior, 7th Edition by Bryan Kol...
TEST BANK For An Introduction to Brain and Behavior, 7th Edition by Bryan Kol...
 
Journal Article Review on Rasamanikya
Journal Article Review on RasamanikyaJournal Article Review on Rasamanikya
Journal Article Review on Rasamanikya
 
Cardiac Assessment for B.sc Nursing Student.pdf
Cardiac Assessment for B.sc Nursing Student.pdfCardiac Assessment for B.sc Nursing Student.pdf
Cardiac Assessment for B.sc Nursing Student.pdf
 
Best Ayurvedic medicine for Gas and Indigestion
Best Ayurvedic medicine for Gas and IndigestionBest Ayurvedic medicine for Gas and Indigestion
Best Ayurvedic medicine for Gas and Indigestion
 
Does Over-Masturbation Contribute to Chronic Prostatitis.pptx
Does Over-Masturbation Contribute to Chronic Prostatitis.pptxDoes Over-Masturbation Contribute to Chronic Prostatitis.pptx
Does Over-Masturbation Contribute to Chronic Prostatitis.pptx
 
A Classical Text Review on Basavarajeeyam
A Classical Text Review on BasavarajeeyamA Classical Text Review on Basavarajeeyam
A Classical Text Review on Basavarajeeyam
 
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptxEar and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
 
Aortic Association CBL Pilot April 19 – 20 Bern
Aortic Association CBL Pilot April 19 – 20 BernAortic Association CBL Pilot April 19 – 20 Bern
Aortic Association CBL Pilot April 19 – 20 Bern
 
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotesPromoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
 
Tests for analysis of different pharmaceutical.pptx
Tests for analysis of different pharmaceutical.pptxTests for analysis of different pharmaceutical.pptx
Tests for analysis of different pharmaceutical.pptx
 
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
 

Annual Epidemiological Presentation, 2017 - Kathleen Brady, PDPH

  • 1. HIV in Philadelphia Kathleen A. Brady, MD Medical Director/Medical Epidemiologist AIDS Activities Coordinating Office Philadelphia Department of Public Health Office of HIV Planning Epi Update February 9, 2017
  • 2. THE HIV CARE CONTINUUM
  • 3. HIV Care Continuum Adapted from Eldred et al AIDS Patient Care STDs 2007;21(Suppl1):S1-S2 Cheever LW Clin Infect Dis 2007;44:1500-2 Not in HIV Care Engaged in HIV Care Unaware of HIV infection Aware of HIV infection (not in care) Receiving some medical care but not HIV care Entered HIV care but lost to follow-up Cyclical or intermittent user of HIV care Fully engaged in HIV care
  • 4. CDC HIV Continuum Measures  Aligns with NHAS 2020 indicator definitions  Represents the best available data for measuring progress  Uses National HIV Surveillance System (NHSS) data which meet the NHAS indicator data source criteria – Timely and routine – Can stratify by demographic characteristics – Prioritized data sources that are available at the state level to allow states ability to monitor progress toward Strategy goals in their jurisdictions  Uses different denominators for each measure
  • 5. Calculation of Indicators  Prevalence of diagnosed HIV – United States – Numerator: Persons aged ≥13 years living with diagnosed HIV infection year-end 2013 – Denominator: Persons aged ≥13 years living with diagnosed or undiagnosed HIV infection year-end 2013 (derived using back- calculation)  The following indicators only use data from areas with complete reporting of CD4 and viral load test results to CDC (32 states and the District of Columbia): – Linkage to care (within 1 month) – Retention in care – Viral suppression
  • 6. Diagnosed Infection among Persons Aged ≥13 Years Living with Diagnosed or Undiagnosed HIV Infection, by Sex, 2013—United States Note. Data include persons with a diagnosis of HIV infection regardless of stage of disease at diagnosis. Estimates were derived by using back- calculation on HIV data for persons aged ≥13 years at diagnosis in the 50 states and the District of Columbia.
  • 7. Diagnosed Infection among Persons Aged ≥13 Years Living with Diagnosed or Undiagnosed HIV Infection, by Age, 2013—United States Note. Data include persons with a diagnosis of HIV infection regardless of stage of disease at diagnosis. Estimates were derived by using back- calculation on HIV data for persons aged ≥13 years at diagnosis in the 50 states and the District of Columbia.
  • 8. Unaware Estimates by Select Demographic Groups, Philadelphia, 2014 Demographic Group % Unaware (95% CI) Sex Female 4.7% (0.0 %-9.8%) Male 7.7% (3.8%-11.2%) Race/Ethnicity Black 8.5% (4.3%-12.4%) Hispanic 4.4% (0%-11.4%) White/Other 5.2% (0.1%-12.2%) Mode of Transmission Heterosexual 9.5% (9.0%-19.1%) IDU (including MSM/IDU) 0.0% (0.0%-2.2%) MSM 9.2% (4.0%-15.0%) Total 7.0% (4.0% – 10.4%) Source: PDPH, AIDS Activities Coordinating Office, 2016
  • 9. EMA Concurrent HIV/AIDS 29.7% 29.1% 26.1% 24.9% 23.5% 0.0% 10.0% 20.0% 30.0% 40.0% 50.0% 2011 2012 2013 2014 2015 Philly PA Counties NJ Counties EMA
  • 10. Concurrent HIV/AIDS, 2014 - 2015 Year 2014 2015 Non-concurrent Concurrent HIV/AIDS Non-concurrent Concurrent HIV/AIDS N Col % N Col % N Col % N Col % Total 444 78.0% 125 22.0% 433 80.5% 105 19.5% Sex Female 89 74.2% 31 25.8% 95 80.5% 23 19.5% Male 35 79.1% 94 20.9% 338 80.5% 82 19.5% Race/ Ethnicity Black 294 76.2% 92 23.8% 312 80.0% 78 20.0% Hispanic 63 88.7% 8 11.3% 66 86.8% 10 13.2% White 70 80.5% 17 19.5% 46 82.1% 10 17.9% Asian 10 76.9% * 23.1% * 45.5% 6 54.5% Multi-race * 50.0% * 50.0% * 50.0% * 50.0% Other/Unk * 75.0% * 25.0% * 100.0% 0 0.0% Source: PDPH, AIDS Activities Coordinating Office, 2016
  • 11. Concurrent HIV/AIDS, 2014 - 2015Year 2014 2015 Non-concurrent Concurrent HIV/AIDS Non-concurrent Concurrent HIV/AIDS N Col % N Col % N Col % N Col % Age at HIV Dx 0-12 * 100.0% 0 0.0% * 100.0% 0 0.0% 13-19 31 93.9% * 6.1% 33 97.1% * 2.9% 20-24 101 91.8% 9 8.2% 96 95.0% * 5.0% 25-29 77 88.5% 10 11.5% 81 88.0% 11 12.0% 30-39 89 74.2% 31 25.8% 101 78.3% 28 21.7% 40-49 62 63.9% 35 36.1% 57 64.8% 31 35.2% 50+ 83 68.6% 38 31.4% 63 68.5% 29 31.5% Transmission Risk MSM 247 84.9% 44 15.1% 253 83.2% 51 16.8% IDU 33 82.5% 7 17.5% 27 90.0% * 10.0% Heterosexual 153 68.0% 72 32.0% 142 75.1% 47 24.9% MSM/IDU 6 100.0% 0 0.0% * 50.0% * 50.0% Pediatric * 100.0% 0 0.0% * 100.0% 0 0.0% No Risk Reported * 66.7% * 33.3% 8 72.7% * 27.3% Source: PDPH, AIDS Activities Coordinating Office, 2016
  • 12. Calculation of Indicators  Linkage to care – Numerator: Persons aged ≥13 years who were diagnosed during 2014 and who had ≥1 viral load (VL) or CD4 test within 1 month of HIV diagnosis – Denominator: Persons aged ≥13 years who were diagnosed during 2014 (32 states and the District of Columbia)
  • 13. Linkage to HIV Medical Care within 1 Month after HIV Diagnosis during 2014, among Persons Aged ≥13 Years, by Sex—32 States and the District of Columbia Note. Data include persons with a diagnosis of HIV infection regardless of stage of disease at diagnosis. Linkage to HIV medical care was defined as having a CD4 or VL test ≤1 month after HIV diagnosis.
  • 14. Linkage to HIV Medical Care within 1 Month after HIV Diagnosis during 2014, among Persons Aged ≥13 Years, by Transmission Category—32 States and the District of Columbia Note. Data include persons with a diagnosis of HIV infection regardless of stage of disease at diagnosis. Linkage to HIV medical care was defined as having a CD4 or VL test ≤1 month after HIV diagnosis. Heterosexual contact is with a person known to have, or be at high risk for, HIV infection. MSM, male-to-male sexual contact; IDU, injection drug use
  • 15. 2011 2012 2013 2014 2015 Linkage 30 Days 75 75 72 77 81 Linkage 90 Days 81 81 78 82 91 0 20 40 60 80 100 Percentage(%) Care Continuum Measures Source: Philadelphia Department of Public Health, AIDS Activities Coordinating Office Philadelphia Linkage to Care Indicators, 2011-2015
  • 16. Calculation of Indicators  Retention in care – Numerator: Persons aged ≥13 years with ≥2 tests (CD4 or VL) at least ≥3 months apart in 2013 – Denominator: Persons aged ≥13 years who were diagnosed by year-end 2012 and alive at year-end 2013 (32 states and the District of Columbia)  Viral suppression – Numerator: Persons aged ≥13 years with <200 copies/mL on their most recent VL test in 2013 – Denominator: Persons aged ≥13 years who were diagnosed by year-end 2012 and alive at year-end 2013 (32 states and the District of Columbia)
  • 17. Retention in HIV Medical Care and Viral Suppression among Persons Aged ≥13 Years Living with Diagnosed HIV Infection, by Sex, 2013—32 States and the District of Columbia Note. Data include persons with a diagnosis of HIV infection regardless of stage of disease at diagnosis. Retained in medical care was defined as ≥2 tests (CD4 or VL) ≥3 months apart in 2013. Viral suppression was defined as <200 copies/mL on the most recent VL test in 2013.
  • 18. Retention in HIV Medical Care and Viral Suppression among Persons Aged ≥13 Years Living with Diagnosed HIV Infection, by Transmission Category, 2013—32 States and the District of Columbia Note. Data include persons with a diagnosis of HIV infection regardless of stage of disease at diagnosis. Retained in medical care was defined as ≥2 tests (CD4 or VL) ≥3 months apart in 2013. Viral suppression was defined as <200 copies/mL on the most recent VL test in 2013. Heterosexual contact is with a person known to have, or be at high risk for, HIV infection. MSM, male-to-male sexual contact; IDU, injection drug use
  • 19. 2011 2012 2013 2014 2015 Retention* 47 51 52 52 53 Suppression* 44 49 50 53 56 0 20 40 60 80 100 Percentage(%) Care Continuum Measures *Significant increase between 2011 and 2015 (p<0.0001) Philadelphia Diagnosis-Based HIV Care Continuum, 2011-2015 Source: Philadelphia Department of Public Health, AIDS Activities Coordinating Office
  • 20. 87% 75% 49% 48% 0% 20% 40% 60% 80% 100% HIV-Diagnosed Linked to Care (2015 New Cases) In HIV Care during 2015 Suppressed VL (<200copies/mL) US Prevalence-Based HIV Care Continuum, 2013 Source: Philadelphia Department of Public Health, AIDS Activities Coordinating Office
  • 21. 93% 91% 49% 52% 0% 20% 40% 60% 80% 100% HIV-Diagnosed Linked to Care (2015 New Cases) In HIV Care during 2015 Suppressed VL (<200copies/mL) 19,280 488/538 10,173 10,758 Philadelphia Prevalence-Based HIV Care Continuum, 2015 Source: Philadelphia Department of Public Health, AIDS Activities Coordinating Office
  • 22. US* Philadelphia** Number 87 Diagnosed 75 Are linked to HIV care 49 Stay in HIV care 48 Have a very low amount of virus in their body Number 93 Diagnosed 91 Are linked to HIV care 49 Stay in HIV care 52 Have a very low amount of virus in their body For every 100 people living with HIV: *2013 Data **2015 Data
  • 24. Newly Diagnosed HIV Cases, Deaths, and Living HIV Cases by Year Philadelphia, 2008-2015 928 897 739 694 737 634 569 538523 513 550 473 434 497 349 312 18640 19237 19525 19157 19832 19564 19494 19280 15000 16000 17000 18000 19000 20000 0 500 1000 1500 2000 2008 2009 2010 2011 2012 2013 2014 2015 Newly Diagnosed Deaths Living HIV Cases Source: PDPH, AIDS Activities Coordinating Office, 2016
  • 25. Rates of Adults and Adolescents Living with Diagnosed HIV Infection, by Area of Residence, Year-end 2014 — United States and 6 Dependent Areas N = 970,319 Total Rate: 360.0 Note. Data include persons with a diagnosis of HIV infection regardless of stage of disease at diagnosis. Data are based on address of residence as of December 31, 2014 (i.e., most recent known address).
  • 26.
  • 27. Persons Living with HIV/AIDS by Census Tract, Philadelphia, 2015 Source: PDPH, AIDS Activities Coordinating Office, 2016
  • 28. Comparison of HIV Prevalence in the US and Philadelphia Philadelphia EMA • 26,807 PLWH as of 12/2015 – 482.6/100,000 population – 1,263.4/100,000 in Philadelphia • 57.9% black, 15.0% Latino, 22.8% white • 70.9% male • 48.8% current age >50 and 24.6% 40-49 • MSM – 35.5%, IDU – 21.3%, Heterosexual – 34.8% • Majority of cases among blacks, regardless of risk United States • 955,081 as of 12/2014 – Rate 299.5/100,000 population • 42.4% black, 20.8% Latino, 31.4% white • 75.6% male • 44.9% current age >50 and 27.6% 40-49 • MSM – 53.3%, IDU – 13.7%, Heterosexual – 25.8% • Highest rates of HIV in the Northeast US Sources: PDPH, AIDS Activities Coordinating Office, 2016 https://www.cdc.gov/hiv/pdf/library/reports/surveillance/cdc-hiv-surveillance-report-2015-vol-27.pdf
  • 29. Proportion of Philadelphia Residents Diagnosed and Living with HIV by Race/Ethnicity and Sex, 2015 2.9% 2.3% 1.1% 1.1% 0.9% 0.2% 0.0% 1.0% 2.0% 3.0% 4.0% 5.0% Black Males Hispanic Males Black Females White Males Hispanic Females White Females Overall Prevalence 1.3% Epidemic Level 1.0% Source: PDPH, AIDS Activities Coordinating Office, 2016
  • 30. Proportion of Philadelphia EMA Residents Diagnosed and Living with HIV by Race/Ethnicity and Sex, 2015 2.9% 2.3% 1.1% 1.1% 0.9% 0.2% 1.0% 0.6% 0.5% 0.1% 0.4% 0.0% 1.0% 0.8% 0.5% 0.2% 0.4% 0.0% 0.5% 1.0% 1.5% 2.0% 2.5% 3.0% 3.5% Black Males Hispanic Males Black Females White Males Hispanic Females White Females Philly PA counties NJ Counties
  • 31. HIV/AIDS Prevalence per 100,000 Population by Race and Transmission Group, 2015
  • 33. Newly Diagnosed HIV Cases, Deaths, and Living HIV Cases by Year Philadelphia, 2008-2015 928 897 739 694 737 634 569 538523 513 550 473 434 497 349 312 18640 19237 19525 19157 19832 19564 19494 19280 15000 16000 17000 18000 19000 20000 0 500 1000 1500 2000 2008 2009 2010 2011 2012 2013 2014 2015 Newly Diagnosed Deaths Living HIV Cases Source: PDPH, AIDS Activities Coordinating Office, 2016
  • 34. Rates of Diagnoses of HIV Infection among Adults and Adolescents, by Area of Residence, 2015 — United States and 6 Dependent Areas N = 39,920 Total Rate: 14.7 Note. Data include persons with a diagnosis of HIV infection regardless of stage of disease at diagnosis. Data for the year 2015 are preliminary and based on 6 months reporting delay.
  • 35. Persons Diagnosed with HIV (regardless of AIDS status) by Census Tract, Philadelphia, 2015 Source: PDPH, AIDS Activities Coordinating Office, 2016
  • 36. Newly Diagnosed HIV United States, 2014 • 44,073 estimated cases • 80.7% male at birth • 43.7% black, 24.3% Hispanic, 26.9% white • 22.0% among 13-24 year olds 66.5% 6.1% 24.1% 2.7%0.4%0.2% Mode of Transmission MSM IDU HET MSM/IDU Pediatric NIR Source: http://www.cdc.gov/hiv/pdf/library/reports/surveillance/cdc-hiv- surveillance-report-us.pdf
  • 37. Newly Diagnosed HIV Philadelphia, 2015 • 538 Newly Diagnosed cases • 78.0% male at birth • 72.4% black, 14.1% Hispanic, 10.4% white • 25.0% among 13-24 year olds 56.5% 5.5% 35.1% 0.4%0.5% 2.0% Mode of Transmission MSM IDU HET MSM/IDU Pediatric NIR Source: PDPH, AIDS Activities Coordinating Office, 2016
  • 38. Newly Diagnosed HIV Disease by Age at Diagnosis (regardless of HIV status) 41 33 222 269 232 197 193 129 111 97 88 127 133 113 121 92 34 33 44 129 120147151 154 164 114 0 50 100 150 200 250 300 2010 2011 2012 2013 2014 2015 Year NumberofCases 13-19 20-29 30-39 40-49 50+
  • 39. Newly Diagnosed HIV Disease by Race/Ethnicity (regardless of HIV status) 105 93 68 87 56 486 508 474 386 390 91 114 69 71 76 0 100 200 300 400 500 600 2010 2011 2012 2013 2014 2015 Year NumberofCases White AfrAm Hispanic
  • 40. Newly Diagnosed HIV Disease by Sex at Birth (regardless of AIDS status) 0 100 200 300 400 500 600 2010 2011 2012 2013 2014 2015 Year NumberofCases HIV Female HIV Male
  • 41. 41 Newly Diagnosed HIV Disease by Mode of Transmission (regardless of AIDS status) 286 300 70 83 40 40 30 250 8 6 11 304 291 322 189 225 313313 30 9 0 50 100 150 200 250 300 350 2010 2011 2012 2013 2014 2015 Year NumberofCases MSM IDU HetSx NIR
  • 42. Rates of Newly Diagnosed HIV/AIDS per 100,000 population, Philadelphia 2011-2015
  • 43. Newly Diagnosed HIV (Non-AIDS) for 2015, Philadelphia EMA EMA Total N=596 EMA % Phila N=433 % PA N=85 % NJ N=78 % Race/Ethnicity White, non-Hispanic 98 16.4 10.6 42.4 20.5 Black, non-Hispanic 399 66.9 72.1 48.2 59.0 Hispanic 87 14.6 15.2 8.2 17.9 Asian/Pacific Islander 7 1.2 1.4 1.2 0.0 American Indian/Alaskan Native <6 0.2 0.2 0.0 0.0 Multi-Race <6 0.3 0.5 0.0 0.0 Gender Male 449 70.2 75.5 72.9 76.9
  • 44. Newly Diagnosed HIV (Non-AIDS) for 2015, Philadelphia EMA EMA Total N=596 EMA % Phila N=433 % PA N=85 % NJ N=78 % Age <13 years <6 0.3 0.8 0.0 0.0 13 - 19 years 38 6.4 7.6 2.4 3.8 20-24 years 128 21.5 22.2 16.5 23.1 25-29 years 121 20.3 18.7 18.8 30.8 30-39 years 127 21.3 23.3 15.3 16.7 40-49 years 79 13.3 13.2 17.6 9.0 50+ years 101 16.9 14.5 29.4 16.7
  • 45. Newly Diagnosed HIV (Non-AIDS) for 2015, Philadelphia EMA EMA Total N=596 EMA % Phila N=433 % PA N=85 % NJ N=78 % Mode of Transmission Men who have sex with men (MSM) 326 54.7 58.4 44.7 4.9 Injection drug users (IDU) 39 6.5 6.2 5.9 9.0 MSM/IDU <6 0.3 0.2 1.2 0.0 Heterosexuals 207 34.7 32.8 41.2 38.5 Other/hemophilia/blood transfusion 0 0.0 0.0 0.0 0.0 Perinatal exposures <6 0.7 0.5 0.0 0.0 Risk not reported or identified 20 5.0 1.8 7.1 7.7
  • 47. 2014 Local Estimate of HIV Incidence • Local estimate of 299 new HIV infections in 2014 in adults and adolescents (95% CI, 205- 393) • Significant reduction since 2012 – 618 estimated HIV infections (95% CI, 419-817) Source: PDPH, AIDS Activities Coordinating Office, 2016
  • 48. HIV Incidence Trends by Demographic Groups 0 200 400 600 800 1000 1200 2006 2007 2008 2009 2011 2012 2013 2014 Total Age 13-24 Male Black MSM Source: PDPH, AIDS Activities Coordinating Office, 2016
  • 49. Estimated Incidence Rates - 2014 Population Population in 2010 (13 +) ESTIMATED Incidence Estimate, 2014 Estimated Case Rate per 100,000 95% CI lower bound 95% CI upper bound MSM 233,550 196 584.2 363.6 801.8 IDU 26,400 33 125.0 22.7 223.5 HET 269,231* 70 26.0 12.3 39.7 *Includes persons >13 living in poverty Data Source: PDPH/AACO HIV Incidence Surveillance Program, 2016
  • 51. Annual Retention, Annual Viral Suppression, and Durable Viral Suppression by Ryan White Care, 2010-2014 52.8 63.3 46 19.2 27.8 20.4 0 20 40 60 80 100 Annual Retention in Care* Annual Viral Suppression* Durable Viral Suppression* Percent(%) Ryan White Non-Ryan White *p<0.0001 Source: Philadelphia Department of Public Health, 2016
  • 52. Philadelphia HIV Care Continuum 2015 0% 20% 40% 60% 80% 100% Diagnosed Linked In Care Retained in Care Prescribed ART Virally Suppressed ALL PLWHA MSM of Color AA Men Youth 13-24 AA Women Transgender Source: PDPH, AIDS Activities Coordinating Office, 2016
  • 53. Philadelphia HIV Care Continuum 2015 0% 20% 40% 60% 80% 100% ALL PLWHA MSM of Color AA Men Youth 13-24 AA Women Transgender Diagnosed Linked In Care Retained in Care Prescribed ART Virally Suppressed Source: PDPH, AIDS Activities Coordinating Office, 2016